[go: up one dir, main page]

UA84903C2 - Фармацевтическая композиция для перорального использования ссі-779, полученная прямым прессованием - Google Patents

Фармацевтическая композиция для перорального использования ссі-779, полученная прямым прессованием

Info

Publication number
UA84903C2
UA84903C2 UAA200608870A UAA200608870A UA84903C2 UA 84903 C2 UA84903 C2 UA 84903C2 UA A200608870 A UAA200608870 A UA A200608870A UA A200608870 A UAA200608870 A UA A200608870A UA 84903 C2 UA84903 C2 UA 84903C2
Authority
UA
Ukraine
Prior art keywords
cci
directly compressible
pharmaceutical compositions
oral use
compressible pharmaceutical
Prior art date
Application number
UAA200608870A
Other languages
English (en)
Ukrainian (uk)
Inventor
Мухаммад Ашраф
Эрик Дж. Бенджамин
Original Assignee
Уайет
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Уайет filed Critical Уайет
Publication of UA84903C2 publication Critical patent/UA84903C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Изобретение относится к фармацевтике, в частности к фармацевтической композиции, которая содержит тонкоизмельченный ССІ-779. Изобретение касается также применения тонкоизмельченного ССІ-779 для получения лекарственного средства и пероральной ССІ-779 лекарственной единицы.
UAA200608870A 2004-01-08 2004-12-14 Фармацевтическая композиция для перорального использования ссі-779, полученная прямым прессованием UA84903C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53495104P 2004-01-08 2004-01-08

Publications (1)

Publication Number Publication Date
UA84903C2 true UA84903C2 (ru) 2008-12-10

Family

ID=34806893

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200608870A UA84903C2 (ru) 2004-01-08 2004-12-14 Фармацевтическая композиция для перорального использования ссі-779, полученная прямым прессованием

Country Status (30)

Country Link
US (1) US20050152983A1 (ru)
EP (1) EP1701698B1 (ru)
JP (1) JP2007517879A (ru)
KR (1) KR20060130162A (ru)
CN (1) CN1921861A (ru)
AR (1) AR047180A1 (ru)
AT (1) ATE383859T1 (ru)
AU (1) AU2004314213A1 (ru)
BR (1) BRPI0418373A (ru)
CA (1) CA2552595A1 (ru)
CR (1) CR8491A (ru)
CY (1) CY1107373T1 (ru)
DE (1) DE602004011398T2 (ru)
DK (1) DK1701698T3 (ru)
EC (1) ECSP066757A (ru)
ES (1) ES2298861T3 (ru)
GT (1) GT200500003A (ru)
HN (1) HN2005000005A (ru)
IL (1) IL176519A0 (ru)
MX (1) MXPA06007829A (ru)
NO (1) NO20062930L (ru)
PA (1) PA8621201A1 (ru)
PE (1) PE20050683A1 (ru)
PL (1) PL1701698T3 (ru)
PT (1) PT1701698E (ru)
RU (1) RU2006122517A (ru)
TW (1) TW200526213A (ru)
UA (1) UA84903C2 (ru)
WO (1) WO2005070393A2 (ru)
ZA (1) ZA200605631B (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005023254A1 (en) 2003-09-03 2005-03-17 Wyeth Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions containing the same
US7268144B2 (en) * 2004-04-14 2007-09-11 Wyeth Regiospecific synthesis of rapamycin 42-ester derivatives
BRPI0510277A (pt) * 2004-04-27 2007-10-30 Wyeth Corp método para marcar especificamente uma rapamicina, rapamicina especificamente marcada, composição, e, kit
US20060183766A1 (en) * 2005-02-15 2006-08-17 Wyeth Orally bioavailable CCI-779 formulations
JP5709354B2 (ja) 2005-11-14 2015-04-30 アリアド・ファーマシューティカルズ・インコーポレイテッド ｍＴＯＲ阻害剤投与によるがん患者の治療
WO2008003050A2 (en) * 2006-06-28 2008-01-03 Emisphere Technologies, Inc. Gallium nitrate formulations
US8430055B2 (en) 2008-08-29 2013-04-30 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US20080175887A1 (en) 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
WO2011151704A2 (en) 2010-06-02 2011-12-08 Fresenius Kabi Oncology Ltd. Stable pharmaceutical compositions of rapamycin esters
US20120087915A1 (en) 2010-06-03 2012-04-12 Pharmacyclics, Inc. Use of inhibitors of bruton's tyrosine kinase (btk)
MX348290B (es) 2012-06-04 2017-06-05 Pharmacyclics Llc Formas cristalinas de un inhibidor de tirosina quinasa de bruton.
MX2015001081A (es) 2012-07-24 2015-10-14 Pharmacyclics Inc Mutaciones asociadas a resistencia a inhibidores de la tirosina cinasa de bruton (btk).
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
CN104721158B (zh) * 2013-12-24 2018-01-30 正大天晴药业集团股份有限公司 一种稳定的依维莫司片剂
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
US20190022073A1 (en) * 2015-09-03 2019-01-24 Nippon Kayaku Kabushiki Kaisha Pharmaceutical composition comprising rapamycin or derivative thereof
WO2017129772A1 (en) 2016-01-29 2017-08-03 Xellia Phamaceuticals Aps Stable pharmaceutical compositions of temsirolimus

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
JP2642486B2 (ja) * 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
US5536729A (en) * 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
US5928668A (en) * 1993-12-21 1999-07-27 Applied Analytical Industries, Inc. Method for dry blend compression of medicaments
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
FR2736550B1 (fr) * 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
WO1998007414A1 (en) * 1996-08-22 1998-02-26 Research Triangle Pharmaceuticals Ltd. Compositions comprising microparticles of water-insoluble substances and method for preparing same
US5989591A (en) * 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
US5985325A (en) * 1997-06-13 1999-11-16 American Home Products Corporation Rapamycin formulations for oral administration
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
NZ538781A (en) * 2002-09-17 2007-11-30 Wyeth Corp Oral formulations
UA83484C2 (ru) * 2003-03-05 2008-07-25 Уайт Способ лечения рака молочной железы комбинацией производного рапамицина и ингибитора ароматазы - летрозола, фармацевтическая композиция
AU2004261163A1 (en) * 2003-07-25 2005-02-10 Wyeth CCI-779 lyophilized formulations
UA83245C2 (en) * 2003-08-07 2008-06-25 Уайт Regioselective synthesis of cci-779
WO2005023254A1 (en) * 2003-09-03 2005-03-17 Wyeth Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions containing the same
US20060142422A1 (en) * 2004-12-07 2006-06-29 Toshikazu Kobayashi Hydrolysis resistant polyester compositions and articles made therefrom
US20060183766A1 (en) * 2005-02-15 2006-08-17 Wyeth Orally bioavailable CCI-779 formulations

Also Published As

Publication number Publication date
GT200500003A (es) 2005-08-18
DE602004011398T2 (de) 2009-01-15
ZA200605631B (en) 2010-01-27
IL176519A0 (en) 2006-10-05
DK1701698T3 (da) 2008-05-05
ES2298861T3 (es) 2008-05-16
EP1701698B1 (en) 2008-01-16
WO2005070393A3 (en) 2006-09-28
AR047180A1 (es) 2006-01-11
ECSP066757A (es) 2006-11-16
JP2007517879A (ja) 2007-07-05
NO20062930L (no) 2006-10-02
WO2005070393A2 (en) 2005-08-04
ATE383859T1 (de) 2008-02-15
EP1701698A2 (en) 2006-09-20
HN2005000005A (es) 2009-04-17
CA2552595A1 (en) 2005-08-04
PT1701698E (pt) 2008-03-27
AU2004314213A1 (en) 2005-08-04
CN1921861A (zh) 2007-02-28
BRPI0418373A (pt) 2007-05-22
TW200526213A (en) 2005-08-16
PL1701698T3 (pl) 2008-03-31
PE20050683A1 (es) 2005-11-04
DE602004011398D1 (de) 2008-03-06
HK1090308A1 (en) 2006-12-22
CR8491A (es) 2008-08-21
CY1107373T1 (el) 2012-12-19
RU2006122517A (ru) 2008-02-20
KR20060130162A (ko) 2006-12-18
MXPA06007829A (es) 2006-09-01
US20050152983A1 (en) 2005-07-14
PA8621201A1 (es) 2005-12-23

Similar Documents

Publication Publication Date Title
UA84903C2 (ru) Фармацевтическая композиция для перорального использования ссі-779, полученная прямым прессованием
WO2008079404A3 (en) Pharmaceutical compositions for treatment of parkinson's disease and related disorders
ES2729679T3 (es) Derivados de morfinano para el tratamiento de la sobredosis de fármacos
EA200501819A1 (ru) Способы и фармацевтические композиции для достоверного достижения приемлемых уровней тестостерона в сыворотке
AU2003225617A1 (en) Thiadiazolylpiperazine derivatives useful for treating or preventing pain
DK1623703T3 (da) Hydrocodonformuleringer med kontrolleret frigivelse
BR0311931A (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar uma doença ou condição mediada com hppar em um paciente
RU2006109467A (ru) Способы лечения рака с использованием ингибиторов hdac
WO2008027350A3 (en) Acetaminophen pharmaceutical compositions
BRPI0707235B8 (pt) formulação de fentanil sublingual sem propelente, e, dispositivo de dose unitária para administração sublingual de uma formulação de fentanil sublingual
WO2008069941A3 (en) Modified release ibuprofen solid oral dosage form
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
NO20022442L (no) Legemidler for sykdommer i forbindelse med reduksjon i benmasse
MX340965B (es) Combinaciones para el tratamiento de enfermedades que involucran la proliferacion celular.
FR15C0009I2 (fr) Compositions de gel phospholipide destinees a l'administration medicamenteuse et des methodes de traitement utilisant celles-ci
TW200621249A (en) Substituted amide beta secretase inhibitors
IL149243A0 (en) Tetrapeptide-l-alanyl-l-glutamyl-l-aspartyl-l-proline and its salts and pharmaceutical compositions containing the same
TW200612909A (en) Compounds
WO2008030752A3 (en) Methods for determining effective doses of fatty acid amide hydrolase inhibitors in vivo
TW200603816A (en) Risedronate compositions and their methods of use
ATE543491T1 (de) Kombinationspräparat enthaltend ibuprofen und paracetamol
EP2392322A3 (en) Dosing regimes for trans-clomiphene
DE60320039D1 (de) Tramadol-formulierungen mit verzögerter freisetzung und 24-stunden-wirksamkeit
ATE283036T1 (de) Pharmazeutische zusammensetzung mit gesteuerter freigabe enthaltend midodrin und/oder desglymidodrin
AU2003281257A8 (en) A novel use of rapamycin and structural analogues thereof